Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Carl Zeiss Meditec owns majority interest
Jena, Germany—Carl Zeiss Meditec AG has acquired 87.1% of IOLTech SA, the French ophthalmic surgery specialist Carl Zeiss Meditec has committed to taking over.
Jena, Germany-Carl Zeiss Meditec AG has acquired 87.1% of IOLTech SA, the French ophthalmic surgery specialist Carl Zeiss Meditec has committed to taking over.
The German company had acquired about 63% of the IOLTech shares from its former principal shareholder as of Feb. 1. About two-thirds of the remaining minority shareholders accepted Carl Zeiss Meditec's voluntary public takeover bid by April 5.
"The company considers this result of the takeover bid as a further successful milestone on Carl Zeiss Meditec's way to the complete takeover of IOLTech," Carl Zeiss Meditec announced.
Related Videos
Related Content
